2'-Fucosyllactose

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
2'-Fucosyllactose
2'-fucosyllactose Drawing.png
Names
IUPAC name
(2R,3R,4R,5R)-4-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal
Other names
2'FL
Identifiers
3D model (JSmol)
UNII
Properties
C18H32O15
Molar mass 488.44 g·mol−1
Density 1.681 g/cm3
240.0 g/L (in water)
Acidity (pKa) 11.9
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

2'-Fucosyllactose (2'-FL) is an oligosaccharide, more precisely, fucosylated, neutral trisaccharide composed of L-fucose, D-galactose, and D-glucose units. It is the most prevalent human milk oligosaccharide (HMO) naturally present in human breast milk, making up about 30% of all of HMOs.[citation needed] It was first discovered in the 1950s in human milk. The oligosaccharide's primary isolation technique has been in use since 1972.[1]

Production[edit]

This compound may be biosynthesized in quantity using E. coli., [2][3][4][5]

Metabolism[edit]

2FL.
The metabolic pathway for GDP--fucose and 2′-fucosyllactose (2-FL) biosynthesis in recombinantE. coli.

Uses[edit]

As with other oligosaccharides, a widely regarded characteristic of 2'-fucosyllactose is its ability to protect against infectious diseases[6] namely in preventing epithelial level adhesions of toxins and pathogens.[7] The 2FL stimulates the growth of certain Bifidobacteria and receptor analogons which lends to toxic and pathogenic protection, all this being most prevalent in infants. Among the pathogens that 2FL is known to protect against are Campylobacter jejuni, Salmonella enterica serotype Typhimurium, Helicobacter pylori, among others.[7]

References[edit]

  1. ^ "Showing metabocard for 2-Fucosyllactose (HMDB02098)". Human Metabolome Database. Retrieved 19 October 2012.
  2. ^ "U of I microbial engineer synthesizes 2-fucosyllactose to protect babies from pathogens". News Medical. Retrieved 19 October 2012.
  3. ^ Chin, Young-Wook; Kim, Ji-Yeong; Lee, Won-Heong; Seo, Jin-Ho (2015). "Enhanced production of 2′-fucosyllactose in engineered Escherichia coli BL21star (DE3) by modulation of lactose metabolism and fucosyltransferase". Journal of Biotechnology. 210: 107–115. doi:10.1016/j.jbiotec.2015.06.431. PMID 26193630.
  4. ^ Chin, Young-Wook; Seo, Nari; Kim, Jae-Han; Seo, Jin-Ho (2016). "Metabolic engineering of Escherichia coli to produce 2'‐fucosyllactose via Salvage pathway of guanosine 5'‐diphosphate (GDP)‐L‐fucose". Biotechnology and Bioengineering. 113: 2443–2452. doi:10.1002/bit.26015. PMID 27217241.
  5. ^ Chin, Young-Wook; Kim, Ji-Yeong; Kim, Jae-Han; Jung, Sang-min; Seo, Jin-Ho (2016). "Improved production of 2'-fucosyllactose in engineered Escherichia coli by expressing putative α-1,2-fucosyltransferase, WcfB from Bacteroides fragilis". Journal of Biotechnology. doi:10.1016/j.jbiotec.2016.11.033. PMID 27919692.
  6. ^ Taylor, Diane E.; Rasko, David A.; Sherburne, Richard; Ho, Clinton; Jewel, Laurence D. (1998). "Lack of correlation between Lewis antigen expression by Helicobacter pylori and gastric epithelial cells in infected patients". Gastroenterology. 115 (5): 1113–1122. doi:10.1016/S0016-5085(98)70082-4. PMID 9797366.
  7. ^ a b Lee, Won-Heong; Pathanibul, Panchalee; Quarterman, Josh; Jo, Jung-Hyun; Han, Nam-Soo; Miller, Michael J; Jin, Yong-Su; Seo, Jin-Ho (2012). "Whole cell biosynthesis of a functional oligosaccharide, 2'-fucosyllactose, using engineered Escherichia coli". Microbial Cell Factories. 11: 48. doi:10.1186/1475-2859-11-48. PMC 3442965. PMID 22545760.